A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Clinical trial NCT02717611 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02717611
- Sponsor
- Acerta Pharma BV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-08
- Primary completion
- 2020-10-16
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.